Hoogland A Marije, Kweldam Charlotte F, van Leenders Geert J L H
Department of Pathology, Josephine Nefkens Institute, Room Be-206, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Biomed Res Int. 2014;2014:341324. doi: 10.1155/2014/341324. Epub 2014 Aug 27.
Prostate cancer is diverse in clinical presentation, histopathological tumor growth patterns, and survival. Therefore, individual assessment of a tumor's aggressive potential is crucial for clinical decision-making in men with prostate cancer. To date a large number of prognostic markers for prostate cancer have been described, most of them based on radical prostatectomy specimens. However, in order to affect clinical decision-making, validation of respective markers in pretreatment diagnostic needle-biopsies is essential. Here, we discuss established and promising histopathological and molecular parameters in diagnostic needle-biopsies.
前列腺癌在临床表现、组织病理学肿瘤生长模式和生存率方面存在差异。因此，对肿瘤侵袭潜能进行个体评估对于前列腺癌男性患者的临床决策至关重要。迄今为止，已经描述了大量前列腺癌的预后标志物，其中大多数基于根治性前列腺切除术标本。然而，为了影响临床决策，在治疗前诊断性穿刺活检中对各个标志物进行验证至关重要。在此，我们讨论诊断性穿刺活检中已确立的和有前景的组织病理学及分子参数。
